TuHURA Biosciences, Inc. (NASDAQ:HURA) has released its financial results for the first quarter ending March 31, 2025. The company's research and development expenses increased to $4.6 million from $3.6 million in the same period in 2024. General and administrative expenses also rose significantly, reaching $2.4 million compared to $1.0 million for the first quarter of 2024. As of March 31, 2025, TuHURA reported approximately 43.7 million total shares outstanding. In terms of business operations, TuHURA plans to initiate a Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma (MCC) in the second quarter of 2025. Additionally, the company has initiated a Phase 1b/2a trial of IFx-Hu2.0 for first-line Merkel cell carcinoma of unknown primary origin (MCCUP). TuHURA is also targeting to complete the acquisition of Kineta, Inc. in the second quarter of 2025 and plans to start a Phase 2 trial of Kineta's VISTA inhibiting monoclonal antibody in NPM1-mutated acute myeloid leukemia in the third quarter of 2025. The company continues to advance its development of bi-specific, bi-functional immune modulating ADCs and APCs, and plans to present non-clinical data at relevant medical meetings throughout the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.